PTEN and tuberous sclerosis: Where causal tests exist, randomized, placebo-controlled everolimus trials in tuberous sclerosis complex and PTEN hamartoma tumor syndrome did not improve prespecified neurocognitive/behavioral composites over 6 months [70,71].